BUZZ-Thermo Fisher falls as 2026 profit midpoint trails estimates** Shares of medical equipment maker Thermo Fisher Scientific TMO.N fall 5% to $577 premarket
** Co expects 2026 adjusted EPS at $24.22–$24.80; midpoint of $24.51 sits below analysts’ avg estimate of $24.61 – data compiled by LSEG
** Co forecasts 2026 revenue of $46.3 bln–$47.2 bln; analysts’ avg estimate is $46.54 bln
** Q4 revenue of $12.22 bln compared with estimate of $11.95 bln
** Exec says Asia Pacific grew low-single-digit in 2025; China declined by mid-single-digit
** Up to previous close, stock had risen 4.1% in the last 12 months
(Reporting by Puyaan Singh and Sahil Pandey)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments